CORT125329 / Corcept Therap - LARVOL DELTA

The Selective Glucocorticoid Receptor Modulator Cort125329 Decreases Neuroinflammation and Gliosis and Enhances Myelination in the Wobbler Model of Amyotrophic Lateral Sclerosis. (PubMed, Mol Neurobiol) - "The beneficial effects of CORT125329 correlated with enhanced motor behavioral performance and trophic changes of the forelimbs. In conclusion, our results support further preclinical and clinical studies on GR modulators in sporadic amyotrophic lateral sclerosis."

IO biomarker • Journal • Amyotrophic Lateral Sclerosis • CNS Disorders • Inflammation • Oncology • Solid Tumor • BDNF • CHAT • HMGB1 • TLR4 • TNFA

Single and Multiple Ascending Dose Study of CORT125329 in Healthy Participants (clinicaltrials.gov) - P1 | N=115 | Completed | Sponsor: Corcept Therapeutics | Recruiting ➔ Completed

Trial completion

Single and Multiple Ascending Dose Study of CORT125329 in Healthy Participants (clinicaltrials.gov) - P1; N=106; Recruiting; Sponsor: Corcept Therapeutics; Trial completion date: Sep 2021 ➔ Feb 2022; Trial primary completion date: Jul 2021 ➔ Dec 2021

Clinical • Trial completion date • Trial primary completion date